STOCK TITAN

Vistagen (NASDAQ: VTGN) CEO receives 75K stock options grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Vistagen Therapeutics reported that President and CEO Shawn Singh received grants of incentive and non-qualified stock options covering a total of 75,000 shares of common stock at an exercise price of $0.5358 per share. According to the grant terms, 25% of the options will vest on the six-month anniversary of April 7, 2026, with additional 25% installments vesting every six months until they are fully vested on the two-year anniversary of the grant date. The options expire on April 7, 2036.

Positive

  • None.

Negative

  • None.
Insider Singh Shawn
Role President and CEO
Type Security Shares Price Value
Grant/Award Incentive Stock Option (right to buy) 3,732 $0.00 --
Grant/Award Non-Qualified Stock Option (right to buy) 71,268 $0.00 --
Holdings After Transaction: Incentive Stock Option (right to buy) — 3,732 shares (Direct); Non-Qualified Stock Option (right to buy) — 71,268 shares (Direct)
Footnotes (1)
  1. [object Object]
Incentive Stock Options granted 3,732 options Grant to CEO Shawn Singh on April 7, 2026
Non-Qualified Stock Options granted 71,268 options Grant to CEO Shawn Singh on April 7, 2026
Total options underlying shares 75,000 shares Combined incentive and non-qualified options granted
Option exercise price $0.5358 per share Strike price for both new option grants
Option expiration date April 7, 2036 End of exercise period for granted options
Initial vesting milestone 25% of options Vest on six-month anniversary of April 7, 2026
Full vesting period 2 years from grant date Options fully vest by two-year anniversary of April 7, 2026
Incentive Stock Option financial
"Incentive Stock Option (right to buy)"
An incentive stock option is a type of employee benefit that gives a worker the right to buy company shares at a fixed price, with special tax advantages if the employee holds the shares for a required period. Think of it as a coupon to buy future shares at today’s price that can result in lower tax on the gain. Investors care because ISOs can dilute share count, align staff incentives with the stock price, and affect company compensation costs and the timing of potential share sales.
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (right to buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
Amended and Restated 2019 Omnibus Equity Incentive Plan financial
"granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan"
vest financial
"25% of the Options will vest on the six-month anniversary"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
Grant Date financial
"until the Options become fully vested on the two (2) year anniversary of the Grant Date"
The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Singh Shawn

(Last)(First)(Middle)
C/O VISTAGEN THERAPEUTICS, INC.
343 ALLERTON AVE

(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Vistagen Therapeutics, Inc. [ VTGN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/07/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Incentive Stock Option (right to buy)$0.535804/07/2026A3,732 (1)04/07/2036Common Stock3,732$0.03,732D
Non-Qualified Stock Option (right to buy)$0.535804/07/2026A71,268 (1)04/07/2036Common Stock71,268$0.071,268D
Explanation of Responses:
1. Represents stock options (the "Options") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. 25% of the Options will vest on the six-month anniversary of April 7, 2026 (the "Grant Date"), and will vest in 25% installments every six months thereafter until the Options become fully vested on the two (2) year anniversary of the Grant Date.
By: Nick B. Tressler, Attorney-in-Fact For: Shawn K. Singh04/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Vistagen (VTGN) disclose about Shawn Singh’s latest equity grant?

Vistagen disclosed that President and CEO Shawn Singh received grants of incentive and non-qualified stock options for 75,000 common shares. These options represent compensation awards, not open-market purchases, and give him the right to buy shares at a fixed exercise price in the future.

What is the exercise price of the new Vistagen (VTGN) CEO stock options?

The newly granted stock options to Vistagen CEO Shawn Singh carry an exercise price of $0.5358 per share. This strike price is the amount he must pay per share if he chooses to exercise the options before they expire in April 2036.

How do the vesting terms work for Shawn Singh’s new VTGN options?

The options vest over two years, with 25% vesting on the six-month anniversary of April 7, 2026. The remaining 75% vest in additional 25% installments every six months, so the grant is fully vested on the two-year anniversary of the grant date.

What types of stock options were granted to the Vistagen (VTGN) CEO?

Shawn Singh received two types of derivative awards: Incentive Stock Options and Non-Qualified Stock Options. Together they cover 75,000 underlying common shares and were granted under Vistagen’s Amended and Restated 2019 Omnibus Equity Incentive Plan as amended.

When do Shawn Singh’s newly granted Vistagen (VTGN) options expire?

Both the incentive and non-qualified stock options granted to Shawn Singh on April 7, 2026 expire on April 7, 2036. He must exercise any vested options before that expiration date or they will lapse and no longer be exercisable.